Current Report Filing (8-k)
August 04 2021 - 9:24AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): August 4, 2021
REDHAWK
HOLDINGS CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-54323
|
20-3866475
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(Employer
Identification No.)
|
|
|
|
100
Petroleum Drive, Suite 200, Lafayette, Louisiana 70508
|
(Address
of principal executive offices) (Zip Code)
|
Registrant’s
telephone number, including area code: (337) 269-5933
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
RedHawk Medical Products and Services, LLC (“RHMP”),
a wholly-owned subsidiary of RedHawk Holdings Corp. (the “Registrant”, “we” or “us”), entered into
an Exclusive Distribution Agreement on July 28, 2021 (the “Agreement”) with a Texas-based medical device distributor (“Distributor”),
for the exclusive global distribution of RHMP’s line of needle incineration devices (“SANDD™”). Under the
Agreement, the Distributor has committed, among other things, to purchase from RHMP, a minimum of 44,500 SANDD mini™, SANDD
HP™ or SANDD FR™ needle incineration devices, 35,000 SANDD Pro™ needle incineration devices, and certain
other medical supplies. The five-year Agreement (with a three year extension if both parties agree) with annual renewals, provides that
RHMP will sell the SANDD™ devices to the Distributor at its customary distributor prices. The Agreement can be terminated
by either party during the term at the end of each anniversary of the Agreement, if either party provides the other at least 30 days prior
notice. The Agreement may also be terminated upon the breach of either party (after a 14 day cure period), including if certain required
minimum sales are not met, and for certain other reasons. The Agreement includes customary intellectual property, confidentiality and
non-compete requirements.
RHMP
expects the initial orders from the Distributor to commence during the three month period ending September 30, 2021, with the
Distributor’s initial marketing efforts focused on sales into certain mutually agreed upon international territories.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REDHAWK HOLDINGS CORP.
|
|
|
Date: August 4, 2021
|
By:
|
/s/
G. Darcy Klug
|
|
|
G. Darcy Klug
|
|
|
Chief Financial Officer
|
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From Aug 2024 to Sep 2024
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From Sep 2023 to Sep 2024